Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 372

The DOI matches its Crossref record; 15 of the 15 references it cites were found in a registry or an index.

Hypertension and COVID-19

Open access
Schiffrin, Ernesto L, Flack, John M, Ito, Sadayoshi, Muntner, Paul, Webb, R Clinton·2020·American Journal of Hypertension

Abstract

The world is currently suffering from the outbreak of a pandemic caused by the severe acute respiratory syndrome coronavirus SARS-CoV-2 that causes the disease called COVID-19, first reported in Wuhan, Hubei Province, China on 31 December 2019.1 As of 29 March 2020, there have been 732,153 confirmed cases of COVID-19 reported worldwide, with 34,686 deaths.2 The clinical and epidemiological features of COVID-19 have been repeatedly published in the last few weeks. Interestingly, specific comorbidities associated with increased risk of infection and worse outcomes with development of increased severity of lung injury and mortality have been reported. The most common comorbidities in one report were hypertension (30%), diabetes (19%), and coronary heart disease (8%).3 Another report showed that the most frequent comorbidities in patients with COVID-19 who developed the acute respiratory distress syndrome were hypertension (27%), diabetes (19%), and cardiovascular disease (6%).4 The frequency with which COVID-19 patients are hypertensive is not entirely surprising nor does it necessarily imply a causal relationship between hypertension and COVID-19 or its severity, since hypertension is exceedingly frequent in the elderly, and older people appear to be at particular risk of being infected with SARS-CoV-2 virus and of experiencing severe forms and complications of COVID-19. It is unclear whether uncontrolled blood pressure is a risk factor for acquiring COVID-19, or whether controlled blood pressure among patients with hypertension is or is not less of a risk factor. However, several organizations have already stressed the fact that blood pressure control remains an important consideration in order to reduce disease burden, even if it has no effect on susceptibility to the SARS-CoV-2 viral infection.5 Nevertheless, the fact that hypertension, and other forms of cardiovascular disease also found frequently in COVID-19 patients, are often treated with angiotensin-converting enzyme (ACE) inhibitors and angiotensin receptor blockers (ARBs), and that SARS-CoV-2, the virus causing COVID-19, binds to ACE2 in the lung to enter cells,6,7 has raised questions regarding the possibility that these agents could either be beneficial or actually nefarious in patients treated with them with respect to susceptibility to acquire COVID-19 or in relation to its outcome. It has been shown that ACE inhibitors and ARBs increase ACE2,8,9 which could theoretically increase the binding of SARS-Cov-2 to the lung and its pathophysiological effects leading to greater lung injury. However, ACE2 has actually been hown to protect from lung injury in experimental studies.10 ACE2 forms angiotensin 1–7 from angiotensin II, and thus reduces the inflammatory action of angiotensin II, and increases the potential for the anti-inflammatory effects of angiotensin 1–7. Accordingly, by reducing either formation of angiotensin II in the case of ACE inhibitors, or by antagonizing the action of angiotensin II by blocking angiotensin AT1 receptors in the case of ARBs,11,12 these agents could actually contribute to reduce inflammation systemically and particularly in the lung, heart, and kidney. Thus, ACE inhibitors and ARBs could diminish the potential for development of either acute respiratory distress syndrome, myocarditis or acute kidney injury, which can occur in COVID-19 patients. In fact, ARBs have been suggested as a treatment for COVID-19 and its complications.13 Increased soluble ACE2 in the circulation could bind SARS-CoV-2, reducing its ability to injure the lungs and other ACE2 bearing organs.14 Using recombinant ACE2 could be a therapeutic approach in COVID-19 to reducing viral load by binding circulating SARS-CoV-2 viral particles and reducing their potential attachment to tissue ACE2. None of these possibilities have however been demonstrated in patients yet. In conclusion, there is as yet no evidence that hypertension is related to outcomes of COVID-19, or that ACE inhibitor or ARB use is harmful, or for that matter beneficial, during the COVID-19 pandemic. Use of these agents should be maintained for the control of blood pressure, and they should not be discontinued, at least on the basis of current evidence at this time.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1093/ajh/hpaa057

Cites

15 of 15 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 15 references

Cited by

See all 372

Metadata

Authors
Schiffrin, E. L., Flack, J. M., Ito, S., Muntner, P., & Webb, R. C.
Venue
American Journal of Hypertension
Published
2020-04-06
Volume
33
Issue
5
Pages
373-374
ISSN
  • 0895-7061 (ISSN-L)
  • 1941-7225
OpenAlex
W3014594373
Cited by
372
References
15
FWCI
10.11
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Hypertension and COVID-19. https://app.cochat.ai/papers/10.1093/ajh/hpaa057
The paper
Schiffrin, E. L., Flack, J. M., Ito, S., Muntner, P., & Webb, R. C. (2020). Hypertension and COVID-19. American Journal of Hypertension. https://doi.org/10.1093/ajh/hpaa057

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.